B. L. Hurst

Ending transmission of SARS-CoV-2: sterilizing immunity using an intranasal subunit vaccine

This paper develops an intranasal multi-antigen vaccine that prevents SARS-CoV-2 infection and transmission by targeting both spike and nucleocapsid proteins.

An intranasal nanoparticle STING agonist has broad protective immunity against respiratory viruses and variants

This study develops NanoSTING, an intranasal nanoparticle STING agonist, showing broad protection against respiratory viruses and variants in animal models.

Vandetanib Reduces Inflammatory Cytokines and Ameliorates COVID-19 in Infected Mice

This study tests FDA-approved kinase inhibitors against SARS-CoV-2 in vitro and in vivo, finding that vandetanib reduces inflammatory cytokines and mitigates lung inflammation in infected mice without reducing viral load.

ProLung™-budesonide Inhibits SARS-CoV-2 Replication and Reduces Lung Inflammation

This paper shows ProLung-budesonide inhibits SARS-CoV-2 replication in vitro and reduces lung inflammation and airway hyperresponsiveness in mice.

High-throughput screening of the ReFRAME, Pandemic Box, and COVID Box drug repurposing libraries against SARS-CoV2 nsp15 endoribonuclease to identify small-molecule inhibitors of viral activity.

The paper screens drug libraries to find inhibitors of SARS-CoV-2 nsp15 endoribonuclease, identifying Exebryl-1 as a potential antiviral compound.

Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine and Pyronaridine: In vitro Activity Against SARS-CoV-2 and Potential Mechanisms

This study evaluates the in vitro antiviral activity of three Ebola and Marburg virus inhibitors against SARS-CoV-2 and explores their potential mechanisms of action.

A cysteine protease inhibitor blocks SARS-CoV-2 infection of human and monkey cells

This paper shows that K777, a cysteine protease inhibitor, blocks SARS-CoV-2 infection by inhibiting host cathepsin L, which is required for spike protein processing, with nanomolar efficacy in several cell lines.